ZESTRIL

This brand name is authorized in Australia, Brazil, Canada, Cyprus, Spain, France, Hong Kong, Ireland, Italy, Japan, Malta, Netherlands, Singapore, United Kingdom, United States, South Africa

Active ingredients

The drug ZESTRIL contains one active pharmaceutical ingredient (API):

1 Lisinopril dihydrate UNII 7Q3P4BS2FD - LISINOPRIL ANHYDROUS

Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion. Read about Lisinopril

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZESTRIL Tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC
ZESTRIL Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C09AA03	Lisinopril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2456G, 2457H, 2458J
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502304901111318, 502304902118316, 502304904110312
Country: CA	Health Products and Food Branch	Identifier(s): 02049333, 02049376, 02049384
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 59127
Country: FR	Base de données publique des médicaments	Identifier(s): 66729161, 67284159
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 147679, 15341, 15343, 15347, 374181, 374194, 374196
Country: HK	Department of Health Drug Office	Identifier(s): 30505, 30515, 30516
Country: IE	Health Products Regulatory Authority	Identifier(s): 52361, 52388, 52396, 53826, 53851, 53867
Country: IT	Agenzia del Farmaco	Identifier(s): 026834010, 026834022
Country: JP	医薬品医療機器総合機構	Identifier(s): 2144006F1022, 2144006F2029, 2144006F3025
Country: MT	Medicines Authority	Identifier(s): MA1310/00201, MA1310/00202, MA1310/00203
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 26646
Country: SG	Health Sciences Authority	Identifier(s): 02369P, 02370P, 02372P
Country: US	FDA, National Drug Code	Identifier(s): 52427-438, 52427-439, 52427-440, 52427-441, 52427-442, 52427-443
Country: ZA	Health Products Regulatory Authority	Identifier(s): V/7.1.3/160, V/7.1.3/161, V/7.1.3/162